Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 3203-3208, December 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Todd, R. F.
Right arrow Articles by Berke, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Todd, R. F., III
Right arrow Articles by Berke, G.

Mechanism of Blocking by Hyperimmune Serum of Lymphocyte-mediated Cytolysis of Allogeneic Tumor Cells1

Robert F. Todd, III, R. Doyle Stulting and Gideon Berke2

Division of Immunology, Duke University Medical Center, Durham, North Carolina 27710

We have investigated the mechanism by which blocking antiserum inhibits lymphocyte-mediated cytolysis of allogeneic tumor cells in vitro. This analysis was made possible by our previous observation that the cytolytic reaction can be experimentally separated into binding and lytic phases. The results show directly that inhibition of lymphocyte-mediated cytolysis can be attributed to prevention of allogeneic tumor cell binding by cytotoxic lymphocytes. Blocking antiserum may also inhibit cytolysis by displacing bound lymphocytes from tumor cells prior to irreversible tumor cell damage.

1 This investigation was supported in part by USPHS Grants TO5-GM-01678, SO4-RR-06148, and RO1-CAAI-14049.

2 On leave of absence from The Weizmann Institute of Science, Rehovot, Israel.

Received 4/23/73. Accepted 9/10/73.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.